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ennifer Franke, MD,* Bernhard Reimers, MD,† Marta Scarpa,† Simonetta Span,†
arcus Thieme, MD,‡ Nina Wunderlich, MD,* Dierk Scheinert, MD,‡ Horst Sievert, MD*
rankfurt and Leipzig, Germany; and Mirano, Italy
bjectives We sought to examine the acute and subacute results of carotid stenting performed
uring live transmissions.
ackground Teaching courses focusing on live demonstrations of carotid interventions have been
he key educational facility for physicians interested in learning state-of-the-art interventional tech-
iques of carotid stenosis treatment. However, starting with the very ﬁrst live demonstration of in-
erventional procedures, there has been an ongoing discussion whether patients treated during live
ransmissions are at higher risk.
ethods Between March 1, 2001, and June 30, 2008, 186 high-grade lesions of the internal carotid
rtery in 186 patients have been treated by stent implantation during live transmissions to 22 inter-
entional conferences at 3 high-volume centers. Technical success was deﬁned as the ability to per-
orm carotid stent implantation. The combined end point of death, major stroke, minor stroke, or
yocardial infarction was deﬁned as primary end point.
esults The procedure was technically successful in 185 of 186 (99.5%) interventions. Seventeen
atients had 1 of the following acute in-hospital complications: major stroke in 2 (1.1%), minor
troke in 3 (1.6%), transient ischemic attack in 11 (5.9%), and amaurosis of the ipsilateral eye due to
n occlusion of the retinal artery in 1 (0.5%). None of the patients died, and no myocardial infarc-
ions occurred. The composite primary end point occurred in 6 (3.2%) patients.
onclusions In this consecutive series of carotid stent cases performed by expert operators during
ive demonstration courses, the procedural and 30-day clinical outcomes were similar to the results
ppearing in the contemporary published data. (J Am Coll Cardiol Intv 2009;2:887–91) © 2009 by
he American College of Cardiology Foundation
rom the *CardioVascular Center Frankfurt, Frankfurt, Germany; †Ospedale di Mirano, Mirano, Italy; and the ‡Department of
ngiology, Heart Center Leipzig, Leipzig, Germany. Dr. Sievert reports having ownership interest in Lumen Biomedical and
erving as a consultant for Kensey Nash, Lumen Biomedical, EndoTex, ev3, Gore, and Invatec. This study was performed in
ompliance with human studies committees of the authors’ institutions. Written informed consent for treatment and live
ransmission of the procedure was received from all patients before the procedure.anuscript received March 24, 2009; revised manuscript received June 1, 2009, accepted June 15, 2009.
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888ranscatheter treatment of carotid stenosis was first re-
orted by Mathias in 1977 (1). Due to the gaining expertise
nd experience of interventionalists, the rapid development
f this endovascular method, as well as the improvement of
erebral protection devices, the periprocedural event rate has
ecreased over the years (2–4). Teaching courses focusing
n live demonstrations of carotid interventions have been
See page 892
he key educational facility for physicians interested in
earning state-of-the-art interventional techniques of ca-
otid stenosis treatment. However, starting with the very
rst live demonstration of interventional procedures, there
as been an ongoing discussion whether patients treated
uring live transmissions are at higher risk. The purpose of
his study is to report the acute and subacute results of
arotid stenting performed during live transmissions, to
ompare the outcome with the results of published carotid
tenting trials.
Methods
Between March 1, 2001, and
June 30, 2008, in-hospital re-
sults of patients with carotid ar-
tery stenosis treated during live
transmissions to 22 international
conferences on endovascular treat-
ment at 3 high-volume centers.
Procedure data, information on
omplications, and follow-up data were collected with con-
erence programs, live case schedules, and patient hospital
ecords and entered prospectively into each center=s data-
ase system. To incorporate the original databases of these
enters, a common database system was developed by the
ardioVascular Center Frankfurt in May 2006. Data re-
eived from procedures before this date were entered retro-
pectively, thereafter in a prospective manner (123 proce-
ures retrospectively and 63 procedures prospectively
ntered into database). The analyzed population consisted
f all patients in whom a carotid procedure was attempted
uring live transmissions to endovascular courses. The
umber of procedures/center is listed in Table 1. No
xclusions were made concerning procedures in which guest
perators were the main operator.
Informed consent for live demonstrations was received
rom all patients before the procedure. The diameter of
tenosis was determined angiographically according to the
ASCET (North American Symptomatic Carotid Endar-
erectomy Trial) measurement criteria (5). Technical success
as defined as the ability to access the carotid artery lesion
bbreviations and
cronyms
EA  carotid
ndarterectomy
IHSS  National Institutes
f Health Stroke Scale
IA  transient ischemic
ttacknd successfully stent the stenosis with a residual stenosis of p20%. Independent neurological examinations including a
eurological assessment according to the National Institutes
f Health Stroke Scale (NIHSS), and clinical examinations
ere performed before and after the procedure, before
ischarge, and at 30 days.
The combined end point of death, major stroke, minor
troke, or myocardial infarction at discharge was defined as
rimary end point. Secondary end point was defined as
eath, major stroke, minor stroke, or myocardial infarction
t 30 days after procedure. Minor stroke was classified as a
ew neurological event that persisted more than 24 h and
hanged the NIHSS score by 2 to 3 points. Major stroke
as defined as a new neurological event that persisted more
han 24 h and changed the NIHSS score by at least 4 points.
mbolic occlusion of the retinal artery was taken into
ccount as a minor stroke. Diagnosis of myocardial infarc-
ion was based on the joint definition of European Society
f Cardiology/American College of Cardiology for acute
yocardial infarction in 2000, then adapted to the defini-
ion of European Society of Cardiology/American College
f Cardiology Foundation/American Heart Association/
orld Heart Federation in 2007 (6,7). Rise and/or fall of
ardiac biomarkers (preferably troponin) was detected with
t least 1 value above the 99th percentile of the upper
eference limit together with evidence of myocardial is-
hemia with at least 1 of the following:
Symptoms of ischemia;
Electrocardiographic changes indicative of new ischemia
(new ST-T changes or new left bundle branch block;
Development of pathological Q waves in the electro-
cardiogram;
Imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality.
Platelet inhibitors (aspirin and clopidogrel) were given in
reparation for the intervention in all patients. Between 0.5
nd 1.0 mg atropine and 5,000 to 10,000 IU of heparin were
dministered routinely during the procedure. Angiography
f the carotid artery was performed to identify the anatom-
cal characteristics of the intracranial and carotid vessels and
o provide information on the lesion. Intracranial circulation
lms were obtained immediately before and after the im-
Table 1. Procedures/Center
Center
Number of
Procedures
CardioVascular Center Frankfurt, Frankfurt, Germany 98
Ospedale di Mirano, Mirano, Italy 34
Department of Angiology, Heart Center Leipzig, Leipzig,
Germany
55lantation procedure to document baseline and final results.
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889esults
he ages of patients ranged from 44 to 89 years (73  8
ears). Forty-one (22.0%) patients were octogenarians; 130
69.9%) were men; 13 patients (7.0%) had a contralateral
cclusion; 95 (51.0%) of the patients suffered from coronary
eart disease, including more than 1 main vessel; 149
80.1%) suffered from hypertension, 62 (33.3%) from dia-
etes, and 104 (55.9%) from hyperlipidemia; and 39
21.0%) were previous or current smokers. Of all patients,
23 (66.1%) had at least 1 high-surgical risk feature (age
80 years, coronary heart disease including more than 1
ain vessel, contralateral occlusion of the internal carotid
rtery, or prior ipsilateral endarterectomy). Twenty-seven
esions (14.5%) were symptomatic. Mean percentage of
esion was 80  13%.
Of the 186 patients treated during live transmissions, the
rocedure was technically successful in 185. In 46 cases
24.7%) an investigational stent or embolic protection de-
ice was chosen. In 1 patient (0.5%) the procedure was
omplicated due to a broken tip of a commercially available
lter embolic protection device. The patient suffered a major
emorrhagic stroke during recovery of the filter tip. In 177
95.2%) lesions the procedure was performed with use of
mbolic protection devices. Proximal occlusion devices were
sed in 40 (21.5%), distal filter systems in 125 (67.2%), and
istal occlusion devices in 7 (3.8%), and the Fibernet
mbolic protection device—which is a combined filter and
istal occlusion system—was used in 5 (2.7%) of the
rocedures. A detailed overview of the embolic protection
evices used during the live demonstrations is listed in
able 2. In none of the procedures was a crossover to a
econd embolic protection device needed.
One hundred seventy-eight carotid stents were im-
lanted. In 3 patients the implantation of a second stent was
Table 2. Overview of the Embolic Protection Devices
Type of Embolic Protection N
Distal occlusion Percusurge GuardWi
TriActiv (Kensey Nas
Twin One (Minvasys
Filter device Spider (ev3, Plymout
Angioguard (Cordis,
Accunet (Guidant/Bo
FilterWire (Boston Sc
Rubicon (Rubicon M
Interceptor (Medtron
Emboshield (Abbott
Proximal occlusion MoMa (Invatec, Ronc
NPS (W. L. Gore & A
Combined Fibernet (Lumen Bio
Totalerformed to completely cover the target lesion. A detailed averview of the carotid stents used during the live demon-
trations is listed in Table 3. In none of the procedures could
he initially chosen stent delivery system not be positioned
r was a crossover to a different stent needed before
mplantation. Pre-dilation of the lesion was performed in 52
f 186 (28.0%). Post-dilation of the carotid stent was
erformed in 176 of 186 (94.6%) of the procedures. Resid-
al stenosis between 20% and 50% after post-dilation was
ound in 41 (22.0%) of the lesions and 50% was found in
(3.8%) of the lesions. Seventeen patients had 1 of the
ollowing acute in-hospital complications: major stroke in 2
1.1%), minor stroke in 3 (1.6%), transient ischemic attack
TIA) in 11 (5.9%), and amaurosis of the ipsilateral eye due
o an occlusion of the retinal artery in 1 (0.5%). No deaths
nd no myocardial infarctions occurred. The composite
rimary end point occurred in 6 (3.2%) patients. The
alculated risk of acute in-hospital complications is listed in
able 4. In the group of patients treated with investigational
evices, the following in-hospital complications occurred:
IA in 2 of 46 (4.3%), and minor stroke in 2 of 46 (4.3%)
atients. In those who were treated with commercially
vailable devices, TIA occurred in 9 of 140 (6.4%), minor
troke including 1 occlusion of the retinal artery in 2 of 140
1.4%), and major stroke occurred in 2 of 140 (1.4%)
atients.
At 30 days after procedure, 3 of 186 patients were lost to
ollow-up, leaving 183 patients for complete examination.
t 30-day follow-up no further deaths, major strokes, minor
trokes, or myocardial infarctions occurred.
iscussion
he debate over safety and live case transmissions dates
ack to the first live demonstrations of interventional
rocedures. Subsequent obstacles of live transmissions such
Patient Cohort
Company) n %
dtronic, Minneapolis, MN) 3 1.7
, PA) 3 1.7
illiers, France) 1 0.6
) 17 9.6
Lakes, FL) 27 15.3
cientiﬁc, Natick, MA) 8 4.7
, Natick, MA) 52 29.4
Boston Scientiﬁc, Natick, MA) 4 2.3
neapolis, MN) 3 1.7
ar, Abbott Park, IL) 14 7.9
, Italy) 32 18.1
es, Inc., Newark, DE) 8 4.5
l, Plymouth, MN) 5 2.8
177in the
ame (
re (Me
h Exton
Genev
h, MN
Miami
ston S
ientiﬁc
edical/
ic, Min
Vascul
adelle
ssociat
medicas distractions of the operator by panel and audience
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890iscussions, timing issues such as short transmission time
indows, the operator’s wish to present novel investiga-
ional devices, a subliminal hesitation to stop an ongoing
rocedure, or hindering transmission equipment in the
atheter laboratory might lead to a more stressful environ-
ent for operators and the staff.
Chatelain et al. (8) first published an article on the success
f coronary angioplasty during live demonstrations in Lancet
n 1992. The results of 104 coronary angioplasty procedures
emonstrated live at 12 international angioplasty courses in
991 were assessed by 1 of the authors= trained interven-
ional cardiologists who participated in the conference as an
nidentified observer. Merely 73% of the initially planned
rocedures were successful. There was a crossover to an-
ther device in 20% and a total success rate of 93%.
hreatened occlusions occurred in 10%, acute occlusions in
%, and delayed occlusions in 2% of all cases. No death or
yocardial infarction was reported. Chatelain et al. (8)
oncluded that “real results of coronary angioplasty are
nferior to those found in publications”—furthermore, “in-
erventions done before an audience will be unusually
tressful but this will be outweighed by the fact that difficult
Table 3. Overview of the Carotid Stents in the Patien
Type of Carotid Stent Name
Closed cell Carotid Wallstent (Bost
Xact (Abbott Vascular,
NexStent (Endotex/Bos
Zilver Stent (Cook, Bloo
Open cell Precise/Smart (Cordis, M
Protégé (ev3, Plymouth
Acculink (Guidant/Abb
Conformexx/Vivexx (Ba
Exponent (Medtronic, M
Sinus Carotid (Optimed
Combined Cristallo Ideale (Invatec
Balloon expandable Tsunami (Terumo, Som
FlexMaster (Abbott Vas
Cypher (Cordis, Miami
Total
Table 4. 30-Day Outcome of Carotid Stenting During Live Transmissions
Complication n %
Minor stoke 3 1.6
Embolic occlusion of the retinal artery 1 0.5
Major stroke 2 1.1
MI 0 0
Death 0 0
All stroke/MI/death 6 3.2
All stroke/death 6 3.2
Major stroke/death 2 1.1MImyocardial infarction.ases with a low probability of success are rarely tackled
uring live courses.”
Some data are available concerning the impact of new
nterventional devices on in-hospital complications con-
erning devices used in coronary interventions. The results
howed that the availability of new transcatheter devices was
ot an independent predictor of complications (9) or, in 1
ublication by Lindsay et al. (10), even proved to enhance
rocedural outcome.
The in-hospital and 30-day outcome of our patients
reated during live transmissions is comparable to results of
arotid stenting reported in major randomized trials in
hich carotid stenting was compared with carotid endarter-
ctomy (CEA). An overview of the results of carotid
ngioplasty/stenting in major randomized trials is presented
n Table 5. The CAVATAS (Carotid and Vertebral Trans-
uminal Angioplasty Study) was the first large study in
hich carotid angioplasty was compared with endarterec-
omy (11). The incidence of major adverse neurological
vents at 30 days was 10% in both the carotid angioplasty
nd CEA groups. The SAPPHIRE (Protected Carotid
rtery Stenting Versus Endarterectomy in High-risk Pa-
Table 5. 30-Day Outcome of Carotid Angioplasty/Stenting in Major
Randomized Trials
Study Inclusion Criteria
Stroke/Death
Rate (%)
CAVATAS 96% Symptomatic lesions 10.0
SAPPHIRE High surgical risk (symptomatic and asymptomatic) 4.5
EVA-3S Symptomatic lesions 9.6
SPACE Symptomatic lesions 6.8
CAVATAS Carotid And Vertebral Artery Transluminal Angioplasty Study; EVA-3S Endarterec-
tomy Versus Angioplasty in patients with Symptomatic Severe carotid Stenosis trial; SAPPHIRE
Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy; SPACE
ort
pany) n %
entiﬁc, Natick, MA) 34 19.1
t Park, IL) 6 3.4
ientiﬁc, Natick, MA) 14 7.9
on, IN) 5 2.8
Lakes, FL) 39 21.9
14 7.9
cular, Abbott Park, IL) 30 16.9
vington, GA) 12 6.7
polis, MN) 4 2.2
gen, Germany) 4 2.2
adelle, Italy) 13 7.3
NJ) 1 0.6
Abbott Park, IL) 1 0.6
FL) 1 0.6
178t Coh
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Lakes,Stent-protected Percutaneous Angioplasty of the Carotid vs. Endarterectomy.
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891ients Study) compared carotid stenting with CEA in
atients with high surgical risk (12). The incidence of major
dverse neurological events at 30 days was 4.5% for the
tented patients and 6.6% for the CEA patients. The
VA-3S (Endarterectomy versus Stenting in Patients with
ymptomatic Severe Carotid Stenosis Trial) compared ca-
otid stenting with endarterectomy in patients with a
ymptomatic carotid stenosis of at least 60% (13). The
0-day incidence of stroke or death was lower in the group
f patients in whom the procedure was performed under
mbolic protection compared with those patients in whom
arotid stenting was performed without embolic protection
18 of 227, 7.9%, vs. 5 of 20, 25%, respectively, p  0.03).
or this reason the stenting arm of the trial without the use
f an embolic protection device was stopped prematurely by
he safety committee. The 30-day risk of any stroke or death
as significantly higher after stenting (9.6%) than after
ndarterectomy (3.9%), which resulted in a relative risk of
.5. In the SPACE (Stent-protected Percutaneous Angio-
lasty of the Carotid versus Endarterectomy), patients with
ymptomatic carotid stenosis of more than 70% in duplex
ltrasound or over 50% according to NASCET measure-
ent were included (14). The use of embolic protection was
ptional. The rate of death or ipsilateral ischemic stroke at
0 days was 6.84% in the group of patients treated with
tent implantation compared with 6.34% in the group of
atients treated with endarterectomy.
onclusions
ive transmissions of carotid stenting and other interven-
ions are an essential component of teaching courses. The
atients and lesions selected for live transmissions represent
he real-world scenario in these centers. The use of inves-
igational devices does not seem to have an impact on the
ercentage of device failures. It can be suggested that
otential causes of difficulties such as distractions by discus-
ions and timing issues such as short transmission time
indows are outweighed by the expertise and experience of
he presenting operators. Interactive discussions with an
xpert panel during the procedure might even influence
ecision making positively by suggesting alternative tech-
iques of treatment that might not have occurred to the
perator. In this consecutive series of carotid stent cases
erformed by expert operators during live demonstration
ourses, the procedural and 30-day clinical outcomes were eimilar to the results appearing in the contemporary pub-
ished data.
eprint requests and correspondence: Dr. Jennifer Franke,
ardioVascular Center Frankfurt, Seckbacher Landstrasse 65,
0389 Frankfurt, Germany. E-mail: jennifer.franke@gmx.net.
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